Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2094192 | 0.89 | NQO2 (0.46) | CYP1A2CYP2C19CYP2C9MTNR1ACYP2D6 | |
| SCHEMBL5013367 | 0.87 | NQO2 (0.45) | CYP1A2CYP2C19CYP2C9MTNR1ACYP2D6 | |
| SCHEMBL2092985 | 0.85 | NQO2 (0.44) | CYP1A2CYP2C19CYP2C9MTNR1ACYP2D6 | |
| SCHEMBL586305 | 0.83 | CYP1A2 (0.52) | CYP1A2CYP2C19CYP2C9MTNR1ACYP2D6 | |
| SCHEMBL3047898 | 0.80 | CYP1A2 (0.62) | CYP1A2CYP2C19CYP2C9MTNR1ACYP2D6 | |
| SCHEMBL16471027 | 0.80 | CYP1A2 (0.48) | CYP1A2CYP2C19CYP2C9MTNR1ACYP2D6 | |
| SCHEMBL791971 | 0.80 | CYP1A2 (0.50) | CYP1A2CYP2C19CYP2C9MTNR1ACYP2D6 | |
| SCHEMBL17435555 | 0.80 | CYP1A2 (0.48) | CYP1A2CYP2C19CYP2C9MTNR1ACYP2D6 | |
| SCHEMBL30487942 | 0.80 | CYP1A2 (0.50) | CYP1A2CYP2C19CYP2C9MTNR1ACYP2D6 | |
| SCHEMBL4514414 | 0.79 | CYP1A2 (0.44) | CYP1A2CYP2C19CYP2C9MTNR1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029695-A1 | METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR | ASUBIO PHARMA CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-7618977-B2 | Method of treating dermatitis comprising administering a chymase inhibitor | ASUBIO PHARMA CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-1192950-B1 | THERAPEUTIC DRUGS FOR DERMATITIS EXHIBITING A BIPHASIC SKIN REACTION CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-07-26 | — | — | EP | disclosed |
| US-6972294-B1 | Compounds, their preparation and use | NOVO NORDISK, A/S (DK) | 2005-12-06 | — | — | US | disclosed |
| US-20040229899-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) | JEPPESEN LONE (DK) | 2004-11-18 | — | — | US | disclosed |
| US-6723731-B2 | 3-(4-(2-(5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLOXY)-ETHOXYL-PHENYL)-2 -ETHOXY-PROPIONIC ACID ETHYL ESTER AS ANTIDIABETIC AGENTS AND TO TREAT OBESITY | NOVO NORDISK A/S (DK) | 2004-04-20 | — | — | US | disclosed |
| US-6703401-B2 | USEFUL IN THE TREATMENT AND/OR PREVENTION OF CONDITIONS MEDIATED BY CLEAR RECEPTORS, IN PARTICULAR THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR). | NOVO NORDISK A/S (DK) | 2004-03-09 | — | — | US | disclosed |
| US-6683111-B2 | SUCH AS 2-ETHOXY-3-(4-(2-XANTHEN-9-YLIDENE-ETHOXY)-PHENYL)-PROPIONIC ACID; FOR TREATING CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; TREATMENT OF DIABETES/OBESITY | NOVO NORDISK A/S (DK) | 2004-01-27 | — | — | US | disclosed |
| US-20030171358-A1 | New compounds, their preparation and use | JEPPESEN LONE (DK) | 2003-09-11 | — | — | US | disclosed |
| US-6602901-B2 | Antidiabetic agents, obesity | NOVO NORDISK A/S (DK) | 2003-08-05 | — | — | US | disclosed |
| WO-2000063153-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000063209-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000023417-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000023451-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000023445-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000023425-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000023416-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000023415-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| US-5814631-A | CHYMASE INHIBITOR, CARDIVASCULAR | SUNTORY LIMITED (JP) | 1998-09-29 | — | — | US | disclosed |
| EP-0795548-A1 | QUINAZOLINE DERIVATIVES AND USE THEREOF | SUNTORY LIMITED (JP) | 1997-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171358-A1 | New compounds, their preparation and use | PPARG, PPARD, PPARA | CYP1A2 283/4885CYP2C19 639/4885CYP2C9 896/4885 |
| US-20040229899-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) | PPARG, PPARA, PPARD | CYP1A2 767/4885CYP2C19 2257/4885CYP2C9 2637/4885 |
| US-20100029695-A1 | METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR | CMA1, DNPEP, SERPINB1 | CYP1A2 2786/4885CYP2C19 3319/4885CYP2C9 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.